2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Gene Editing, Treatment Considerations, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Thrombotic Disorders, Genetic Disorders, Immunology, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

2995 Deficiency of the GARP–TGF-β1 axis contributes to impaired megakaryocyte reconstitution after allogeneic hematopoietic stem cell transplantation

Xiaofei Song, Jiaqian Qi, MD, PhD2, Yaqiong Tang3, Meng Zhou4, Depei Wu Sr, MD5, Han Yue, MD,PhD6
1 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China, National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
2 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China, National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
3 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China, National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
4 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China, National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
5 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China, National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
6 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China, National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

Introduction: Prolonged isolated thrombocytopenia (PIT) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) increases bleeding risk, yet how the bone marrow (BM) niche regulates post-transplant megakaryopoiesis remains unclear. Although soluble active TGF-β1 has been reported to suppress megakaryopoiesis in some experimental settings, GARP (LRRC32) presents latent TGF-β1 on megakaryocytes and platelets, potentially regulating its local availability and context-dependent signaling. We investigated whether disruption of this axis contributes to impaired megakaryocyte reconstitution in PIT.

Methods: PIT was defined as a platelet count ≤30×109/L beyond day 60 despite complete donor chimerism, in the absence of relapse, severe GVHD, active infection, transplant-associated thrombotic microangiopathy, or other recognized causes of thrombocytopenia. GGF was defined as sustained, transfusion-independent trilineage recovery with complete donor chimerism. The study had ethics approval, and written informed consent was obtained from all participants. Total BM TGF-β1 and immune mediators were measured by acid-activation ELISA and a flow cytometry-based multiplex bead assay, respectively. Human CD34+ cells underwent 12-day megakaryocytic differentiation with SCF, TPO, IL-3, IL-6, and FLT3L. Megakaryocyte progenitors (MKPs, CD34+CD38+CD45RA-CD123-CD41+), CD41/CD61, and polyploidy were quantified by flow cytometry; CD41/GARP localization, F-actin, proplatelet-like morphology, and p-SMAD2 were assessed by immunofluorescence. Cultures were exposed to BM supernatants derived from patients with PIT or GGF, with or without recombinant GARP-latent TGF-β1 complex (100 ng/mL). MEG-01 and primary CD34+ cells were transduced with GARP-expressing or control lentiviral vectors. Immunoblotting assessed MEG-01 p-SMAD2/SMAD2 at 1, 6, and 24 hours after treatment with active TGF-β1 (5 ng/mL) or complex (500 ng/mL) treatment, as well as TGF-β1 forms in GARP-overexpressing cells. In a low graft-dose C57BL/6-to-BALB/c allo-HSCT model, mice received 0.5 or 2 μg of the complex on days 0, 2, and 4; serial blood counts, BM progenitors/megakaryocytes, histology, donor chimerism, and nuclear p-SMAD2 were assessed. A two-sided P < 0.05 was considered statistically significant.

Results: Compared with patients with GGF, patients with PIT had lower BM CD34+CD41+ fractions, total TGF-β1 (P < 0.0001), and proportions of CD41+GARP+ cells (P < 0.01). PIT BM supernatants showed a proinflammatory cytokine/chemokine profile, with increased CCL2, CXCL10, and TNF-α and reduced IL-10. These supernatants reduced MKP counts (1279 ± 255 vs 2196 ± 165, P < 0.01) and impaired CD41/CD61 acquisition and polyploidization. In megakaryocyte cultures derived from primary human CD34+ cells,  the complex expanded MKPs; increased the proportions of day-7 CD41+ cells (72.66 ± 1.74% vs 52.26 ± 0.81%, P < 0.0001) and CD61+ cells (46.38 ± 1.36% vs 23.85 ± 0.41%, P < 0.0001); enhanced ≥8N polyploidization (33.97 ± 1.57% vs 18.43 ± 2.12%, P < 0.001); and partially alleviated PIT-supernatant-mediated suppression. Qualitative immunofluorescence showed greater CD41/GARP colocalization on day 6 and, on day 12, larger CD41+ cells with enhanced F-actin organization, proplatelet-like extensions, and p-SMAD2 staining. MEG-01 immunoblotting showed stronger p-SMAD2 at 1, 6, and 24 hours after treatment with the complex. GARP overexpression in MEG-01 cells increased the proportion of cells coexpressing surface GARP and latency-associated peptide (LAP), as well as precursor- and mature-form TGF-β1 immunoreactivity. It also attenuated suppression by 5% PIT-derived BM supernatant relative to vector controls. Mice in the low graft-dose model developed sustained thrombocytopenia and had reduced BM MKPs, CD41+ cells, and megakaryocytes despite near-complete donor chimerism. Early treatment with 2 μg of the complex mitigated the platelet nadir, improved subsequent recovery, and increased the number of BM megakaryocytes per high-power field and nuclear p-SMAD2 MFI in BM CD41+ cells.

Conclusion: PIT after allo-HSCT is associated with attenuation of the GARP–TGF-β1 axis and impaired megakaryocyte reconstitution. Augmenting this axis enhanced SMAD2 signaling, megakaryopoiesis, and platelet recovery, supporting the therapeutic potential of targeting this axis.

Xiaofei Song: No relevant conflicts of interest to declare.